Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer |
| |
Authors: | Attard G,Clark J,Ambroisine L,Mills I G,Fisher G,Flohr P,Reid A,Edwards S,Kovacs G,Berney D,Foster C,Massie C E,Fletcher A,De Bono J S,Scardino P,Cuzick J,Cooper C S Transatlantic Prostate Group |
| |
Affiliation: | Institute of Cancer Research, Male Urological Cancer Research Centre, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. |
| |
Abstract: | A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer. |
| |
Keywords: | prostate cancer ETV1 ACSL3 ACSL3:ETV1 fusion |
本文献已被 PubMed 等数据库收录! |
|